Global Infliximab And Biosimilar Market Size By Geographic Scope And Forecast

Infliximab And Biosimilar Market Size And Forecast

Infliximab And Biosimilar Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2022 to 2030.

The fact that numerous biological innovative products, including monoclonal antibodies (mAbs), are nearing patent expiration is a major driver for the Infliximab And Biosimilar Market. Growing research into developing biosimilars for these is a key trend that is boosting potential growth. The Global Infliximab And Biosimilar Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Infliximab And Biosimilar Market Definition

Think of biosimilars as being a lot like brand-name medications! They're biological products that are highly similar to medicines already given the green light by the FDA. These aren't just knock-offs; they've been carefully reviewed and approved by groups like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They're considered to have no major differences in things like safety and how well they work. And, they're only approved for the same uses that the original ("reference") product was approved for. For example, infliximab, a monoclonal antibody developed together by Janssen Biotech Inc. and Merck & Co. (MSD) and first OK'd by the FDA way back in 1998, is used to help both adults and kids dealing with Crohn’s disease.

Global Infliximab And Biosimilar Market Overview

The Rising incidence of autoimmune diseases, particularly in rheumatoid arthritis and plaque psoriasis, discounted pricing across the European market, and faster reaction times due to an intravenous mode of administration are all driving factors for the Remicade biosimilar. Furthermore, introducing biosimilar versions could give financial relief to healthcare systems while also improving patients’ access to essential medications. The Remicade biosimilar’s barriers include substantial adverse effects linked with drug use that could lead to hospitalization or even death in rare cases.

The rising prevalence of relevant autoimmune illnesses and reduced Remicade biosimilar pricing in European markets are projected to contribute to higher referral and consumption of the medicine. Faster approval procedures and appropriate U.S. FDA-certified manufacturing facilities in regional nodal nations are variables that contribute to increasing drug acceptance. Furthermore, differentiated nomenclature and visible labeling to enable proper prescribing and dispensing and enhanced post-marketing surveillance are variables that could contribute significantly to prescriber confidence and increased market penetration in the coming years.

Global Infliximab And Biosimilar Market Segmentation Analysis

The Global Infliximab And Biosimilar Market is Segmented on the basis of Geography.

Infliximab And Biosimilar Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Infliximab And Biosimilar Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Europe leads the Infliximab And Biosimilar Market, followed by Japan and Latin America. The primary reason for this is the release of the biosimilar version soon after the branded version’s patent expiration.

Key Players

The “Global Infliximab And Biosimilar Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc. (AC. Hospira), Janssen Biotech Inc., Merck &Co., Celltrion Inc., Alvogen, Napp Pharmaceuticals, and Nippon Kayaku.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In Sep 2016, Pfizer Inc. announced the confirmatory study (REFLECTIONS B537-02) comparing the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) to Remicade® (infliximab) met its primary endpoint. The proposed biosimilar PF-06438179 demonstrated equivalent efficacy to the originator product as measured by the American College of Rheumatology 20 (ACR20) response at Week 14. PF-06438179 is being developed as a Remicade biosimilar.

• In July 2017, Merck & Co. Announced the U.S. Launch of RENFLEXIS™ (infliximab-abda), a Biosimilar of Remicade, for All Eligible Indications.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We take a deep dive into the market, looking at it from every angle – not just the money side, but also how people really behave. We'll give you the USD Billion value for every piece of the market, big and small. You'll see exactly which regions and segments are set to explode with growth and which ones are already on top. Plus, we'll break down what's driving (or holding back) the market in each area, showing you how people are actually using the product or service. Speaking of competition, we'll rank the big players and give you the scoop on all the new stuff they're launching, the deals they're making, and how they're expanding. Each major player gets a full company profile – think company history, insights, product benchmarking, and even a SWOT analysis. We’ll also provide our expert take on where the market is headed, spotlighting emerging opportunities, growth drivers, and the hurdles that lie ahead in both up-and-coming and established areas. To understand the power dynamics, we'll use Porter's five forces. You'll also get a handle on the Value Chain, seeing how everything connects. Finally, we'll paint a picture of the market's future and where the best growth opportunities will be. And don't forget – you get 6 months of analyst support after the sale to help you make sense of it all!

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.